Final results from Pfizer Inc.’s Covid-19 vaccine trial showed the company’s shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days.
Pfizer-BioNTech and Moderna’s Vaccines Lead the Covid-19 Race; How Do They Compare?
"Operation Warp Speed" Initiative, AstraZeneca, BioNTech, Business, Clinical Trials, Cold chain storage, COVID-19 Vaccines, Efficacy Data, FDA, Interim Data, Messenger RNA (mRNA) Vaccines, Moderna, National Institute of Allergy and Infectious Diseases (NIAID), NPR, Oxford University, Pfizer, R&D, U.S. government, United StatesBioSpace takes a look at Moderna at the similarities between the two, and a few differencesPfizer-BioNTech and Moderna Covid-19 vaccines preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, the U.S. and western countries have the promise of two effective and reasonably safe vaccines. There are . Here’s a look.
EVERSANA, the leading independent provider of global services to the life science industry, announced that expansions to the company’ cold chain storage capabilities are complete and ready to meet the growing 3PL and complex channel distribution needs of the pharmaceutical industry.